Consolidated Statements of Stockholders' Equity (Deficit) - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Treasury Stock	Accumulated Deficit	Total Vaccinex,Inc. Stockholders' Equity (Deficit)	Noncontrolling Interests
Balance at Dec. 31, 2019	$ (2,274)	$ 1	$ 222,403	$ (11)	$ (248,630)	$ (26,237)	$ 23,963
Balance, Shares at Dec. 31, 2019		14,887,999		852
Issuance of Common Shares	28,475	$ 2	28,473			28,475
Issuance of common shares, Shares		7,450,004
Stock-based compensation	732		732			732
Stock-based compensation, Shares		20,000
Exercise of stock options	$ 19		19			19
Exercise of stock options, Shares	3,783	3,783
Exchange of Vaccinex Products LP Units/ partnership units for common shares, Shares		26,241
Common shares issuance costs	$ (713)		(713)			(713)
Net loss	(28,851)				(28,851)	(28,851)
Balance at Dec. 31, 2020	(2,612)	$ 3	250,914	$ (11)	(277,481)	(26,575)	23,963
Balance, Shares at Dec. 31, 2020		22,388,027		852
Issuance of Common Shares	32,848		32,848			32,848
Issuance of common shares, Shares		5,937,900
Stock-based compensation	541		541			541
Exchange of Vaccinex Products LP Units/ partnership units for common shares			23,963			23,963	$ (23,963)
Exchange of Vaccinex Products LP Units/ partnership units for common shares, Shares		2,466,056
Common shares issuance costs	(985)		(985)			(985)
Shares issued for compensation, Shares		9,979
Net loss	(22,380)				(22,380)	(22,380)
Balance at Dec. 31, 2021	$ 7,412	$ 3	$ 307,281	$ (11)	$ (299,861)	$ 7,412
Balance, Shares at Dec. 31, 2021		30,801,962		852